Biotechnology Equipment Genome-based Drug Discovery

PUBLISHER: 360iResearch | PRODUCT CODE: 2094401

PUBLISHER: 360iResearch | PRODUCT CODE: 2094401

Metagenomic Sequencing Market - Global Forecast 2026-2032

PUBLISHED: July 22, 2026

PAGES: 181 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Metagenomic Sequencing Market is projected to grow by USD 6.65 billion at a CAGR of 14.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 2.63 billion
Estimated Year [2026]	USD 2.99 billion
Forecast Year [2032]	USD 6.65 billion
CAGR (%)	14.15%

Metagenomic sequencing is reshaping microbiome research, infectious disease surveillance, antimicrobial resistance monitoring, environmental genomics, food safety, agriculture, and biomanufacturing by enabling culture-independent analysis of genetic material recovered directly from complex samples. Unlike targeted assays that detect predefined organisms, shotgun metagenomic sequencing and metagenomic next-generation sequencing can characterize bacteria, viruses, fungi, archaea, parasites, functional genes, virulence markers, and resistance determinants in a single workflow. The field is being strengthened by lower sequencing costs, higher-throughput instruments, portable sequencing platforms, richer reference databases, and improved bioinformatics pipelines that convert large-scale sequence reads into clinically and operationally meaningful insights. Demand is also supported by public health priorities such as pathogen genomics, wastewater surveillance, One Health programs, hospital infection control, and foodborne outbreak investigation. As adoption expands, stakeholders are increasingly focused on analytical validation, contamination control, sample preparation consistency, data interoperability, regulatory readiness, privacy safeguards, and reproducible interpretation to ensure that metagenomic sequencing delivers reliable value across research, diagnostics, and industrial applications.

Transformative Shifts in the Metagenomic Sequencing Landscape

The metagenomic sequencing landscape is undergoing transformative shifts as the technology moves from research-centered use toward applied decision-making in healthcare, environmental monitoring, agriculture, and public health. Clinical microbiology laboratories are evaluating metagenomic next-generation sequencing to support diagnosis of complex infections, particularly when conventional culture is negative, slow, or limited by prior antimicrobial exposure. Public health agencies are expanding genomic epidemiology capabilities, with wastewater-based surveillance demonstrating utility for tracking viral pathogens, antimicrobial resistance signals, and community-level health trends. In agriculture and food systems, metagenomics is increasingly used to assess soil microbial ecology, animal health, fermentation quality, contamination risks, and supply chain safety. At the technology level, long-read sequencing is improving assembly, strain resolution, plasmid analysis, and antimicrobial resistance gene context, while short-read sequencing remains valuable for depth, cost efficiency, and established analytical workflows. Cloud-based bioinformatics, standardized reporting formats, laboratory automation, and integrated quality control are reducing barriers to adoption. However, persistent challenges remain, including host DNA depletion, low-biomass contamination, database bias, interpretation of incidental findings, and the need for harmonized standards across laboratories and jurisdictions.

Cumulative Impact of Artificial Intelligence on Metagenomic Sequencing

Artificial intelligence is accelerating the practical utility of metagenomic sequencing by improving signal detection, taxonomic classification, functional annotation, outbreak clustering, antimicrobial resistance prediction, and workflow automation. Machine learning methods can help distinguish true microbial signatures from background contamination, prioritize clinically relevant organisms, and identify patterns across high-dimensional multi-omics datasets. AI-enabled pipelines are increasingly used to compress analysis timelines, support real-time surveillance dashboards, improve sequence read classification, and integrate metagenomic data with epidemiological, clinical, environmental, and geospatial information. In antimicrobial resistance monitoring, predictive models can link resistance genes, mobile genetic elements, and host organisms more effectively when supported by curated databases and validated training sets. In environmental and industrial microbiology, AI can reveal community dynamics that influence soil productivity, wastewater treatment performance, fermentation stability, and ecosystem health. The cumulative impact of AI will depend on transparent model validation, high-quality reference datasets, bias mitigation, explainable outputs, cybersecurity controls, and governance frameworks that ensure responsible use. Organizations that combine robust laboratory methods with AI-driven analytics are better positioned to transform raw sequencing reads into actionable microbial intelligence.

Key Regional Insights Across Global Metagenomic Sequencing Adoption

Asia-Pacific is emerging as a highly dynamic region for metagenomic sequencing due to expanding genomics infrastructure, national precision medicine programs, infectious disease surveillance priorities, and growing investment in biotechnology across major economies. Regional use cases span hospital diagnostics, microbiome research, aquaculture, agriculture, food safety, and environmental monitoring, with dense urban populations and biodiversity-rich ecosystems creating strong demand for microbial intelligence. Europe benefits from coordinated research frameworks, cross-border pathogen surveillance, stringent quality requirements, and active microbiome and One Health initiatives, making harmonization, data protection, and standardization central to regional adoption. North America demonstrates mature adoption supported by advanced sequencing capacity, strong academic and public health genomics networks, antimicrobial resistance initiatives, wastewater surveillance programs, and established translational research infrastructure. Latin America is increasingly applying metagenomic sequencing to infectious disease surveillance, tropical disease research, biodiversity studies, agricultural productivity, and foodborne pathogen monitoring, although uneven laboratory capacity and funding variability can influence implementation depth. Africa presents critical opportunities for metagenomic sequencing in outbreak detection, antimicrobial resistance surveillance, zoonotic disease monitoring, biodiversity research, and wastewater epidemiology, while capacity building, sequencing accessibility, workforce development, and data infrastructure remain essential for sustainable deployment. The Middle East is advancing genomics and public health modernization through national healthcare transformation programs, infectious disease preparedness, food security initiatives, and environmental monitoring in arid ecosystems.

Key Group Insights Shaping Metagenomic Sequencing Priorities

NATO member states place growing emphasis on biosecurity, biosurveillance, pathogen detection, military health protection, and resilient public health infrastructure, making metagenomic sequencing relevant for preparedness, rapid response, and cross-border risk assessment. G7 countries generally demonstrate advanced sequencing infrastructure, strong regulatory engagement, high research intensity, and increasing integration of metagenomic data into public health, clinical microbiology, antimicrobial resistance monitoring, and environmental surveillance. The European Union emphasizes coordinated research funding, cross-border data sharing frameworks, clinical validation, privacy-compliant genomic data governance, and One Health surveillance, creating a structured environment for metagenomic sequencing applications in healthcare, agriculture, and environmental science. BRICS economies show broad relevance for metagenomics across large population health systems, emerging biotechnology sectors, agriculture, wastewater monitoring, and infectious disease surveillance, although infrastructure maturity differs by country. Within ASEAN, metagenomic sequencing adoption is closely linked to infectious disease monitoring, food safety, aquaculture, agricultural resilience, and tropical biodiversity research, with regional collaboration becoming increasingly important for pathogen surveillance and antimicrobial resistance tracking. GCC countries are integrating genomics into healthcare modernization, national laboratory development, environmental surveillance, food security, and infectious disease preparedness, supported by strong interest in digital health and advanced diagnostics.

Key Country Insights for Metagenomic Sequencing Development

The United States is a central hub for metagenomic sequencing innovation, with strong activity in clinical metagenomics, wastewater surveillance, antimicrobial resistance monitoring, microbiome science, and public health genomics. China has rapidly expanded sequencing infrastructure and applies metagenomics across infectious disease surveillance, agriculture, environmental monitoring, hospital research, and microbiome science. Germany is active in biomedical research, industrial biotechnology, antimicrobial resistance programs, and environmental microbiome studies, supported by strong laboratory and engineering capacity. Japan focuses on precision health, microbiome science, food safety, environmental genomics, and advanced sequencing workflows. India is strengthening genomics networks for public health, antimicrobial resistance tracking, wastewater surveillance, agriculture, and infectious disease research. The United Kingdom combines strong genomics expertise with public health sequencing infrastructure, clinical microbiology research, and wastewater monitoring capabilities. France emphasizes infectious disease research, food safety, microbiome science, and One Health surveillance, while Canada emphasizes infectious disease surveillance, Arctic and environmental microbiome research, food safety, and integrated public health laboratory capabilities. Italy and Spain are advancing metagenomic applications in clinical research, food systems, environmental surveillance, and microbiome studies. Australia applies metagenomic sequencing to biosecurity, environmental monitoring, agriculture, public health, and marine ecosystems, while South Korea demonstrates strong capacity in clinical research, infectious disease preparedness, biotechnology, and digital health integration. Brazil has significant relevance in tropical disease genomics, biodiversity, agriculture, wastewater epidemiology, and antimicrobial resistance surveillance due to its large population base and ecological diversity. Mexico is applying metagenomics to foodborne pathogens, agricultural systems, microbiome research, and infectious disease studies, with opportunities tied to laboratory network strengthening. Russia applies sequencing to infectious disease monitoring, environmental research, agriculture, and public health preparedness.

Actionable Recommendations for Metagenomic Sequencing Leaders

Industry leaders should prioritize validated, end-to-end metagenomic sequencing workflows that integrate optimized sample collection, nucleic acid extraction, host depletion where appropriate, library preparation, sequencing, bioinformatics, and interpretive reporting. Establishing rigorous quality control is essential, particularly for low-biomass samples where contamination can distort findings. Organizations should invest in curated reference databases, transparent analytical pipelines, and reproducible reporting standards to improve confidence among clinicians, regulators, public health officials, and industrial users. Strategic partnerships with hospitals, public health laboratories, agricultural agencies, environmental authorities, and academic groups can accelerate real-world validation and broaden application pathways. Leaders should also build AI capabilities responsibly by using validated datasets, explainable models, and human-in-the-loop review for high-consequence decisions. Data governance must address privacy, cybersecurity, consent, cross-border data transfer, and ethical considerations, especially when human host reads or sensitive outbreak data are involved. Workforce development in bioinformatics, molecular microbiology, quality management, and regulatory science will be critical. Finally, organizations should design flexible workflows that can support both routine surveillance and rapid response during outbreaks, contamination events, or emerging pathogen threats.

Research Methodology for Metagenomic Sequencing Insights

This executive summary is developed through a structured secondary research approach using verified scientific, regulatory, public health, and industry-relevant sources, including peer-reviewed literature, public health agency publications, genomic surveillance guidance, antimicrobial resistance reports, wastewater surveillance documentation, standards-oriented materials, and publicly available policy resources. The methodology emphasizes triangulation across multiple credible sources to assess technology adoption patterns, use-case maturity, regional priorities, AI integration, and operational barriers in metagenomic sequencing. Evidence is evaluated for relevance, recency, scientific reliability, and applicability across healthcare, environmental, agricultural, food safety, and public health contexts. The analysis excludes unsupported claims and avoids market sizing, market share, and forecasting. Insights are organized to reflect technology drivers, implementation challenges, geographic adoption dynamics, and strategic implications for decision-makers. Particular attention is given to validation requirements, sequencing workflow quality, bioinformatics reproducibility, reference database limitations, data governance, and real-world deployment considerations.

Conclusion: Metagenomic Sequencing as a Strategic Microbial Intelligence Platform

Metagenomic sequencing is becoming a foundational technology for culture-independent microbial analysis, enabling broader detection, faster investigation, and deeper functional understanding across healthcare, public health, agriculture, food safety, and environmental systems. Its value is strongest where complex microbial communities, unculturable organisms, antimicrobial resistance, outbreak signals, or ecosystem-level interactions must be assessed with high resolution. Artificial intelligence, long-read and short-read sequencing integration, laboratory automation, cloud bioinformatics, and standardized surveillance frameworks are improving usability and scalability. At the same time, success depends on validated methods, contamination control, high-quality reference databases, skilled interpretation, and responsible data governance. Regions and countries with strong genomics infrastructure, coordinated public health systems, and interdisciplinary collaboration are best positioned to convert metagenomic data into actionable intelligence. As adoption broadens, industry leaders that focus on analytical reliability, transparent reporting, regulatory alignment, and practical decision support will be better equipped to unlock the full potential of metagenomic sequencing.

Product Code: MRR-E3708867678B

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Metagenomic Sequencing Market, by Product Type

7.1. Introduction
7.2. Bioinformatics & Analysis Tools
- 7.2.1. Data Analysis Software
- 7.2.2. Data Management & Storage Solutions
- 7.2.3. Interpretation Tools
7.3. Consumables & Kits
- 7.3.1. Enrichment Kits
- 7.3.2. Library Preparation Kits
- 7.3.3. Reagents
- 7.3.4. Sequencing Kits
7.4. Instruments
7.5. Services
- 7.5.1. Custom Assay Services
- 7.5.2. Data Analysis Services
- 7.5.3. Sequencing Services

8. Metagenomic Sequencing Market, by Sample Type

8.1. Introduction
8.2. Agricultural Samples
- 8.2.1. Plant Tissues
- 8.2.2. Soil
8.3. Clinical Samples
- 8.3.1. Blood
- 8.3.2. Stool
- 8.3.3. Tissue
8.4. Environmental Samples
- 8.4.1. Air
- 8.4.2. Soil
- 8.4.3. Water
8.5. Food Samples
- 8.5.1. Dairy
- 8.5.2. Meat & Poultry
- 8.5.3. Produce

9. Metagenomic Sequencing Market, by Technology

9.1. Introduction
9.2. Long-Read Sequencing
9.3. Short-Read Sequencing

10. Metagenomic Sequencing Market, by Throughput

10.1. Introduction
10.2. Low-throughput Sequencing
10.3. High-throughput Sequencing
10.4. Medium-throughput Sequencing

11. Metagenomic Sequencing Market, by Application

11.1. Introduction
11.2. Academic Research
11.3. Clinical Diagnostics
- 11.3.1. Genetic Disorder Detection
- 11.3.2. Infectious Disease Profiling
- 11.3.3. Microbiome Analysis
- 11.3.4. Oncology Research
11.4. Environmental Studies
11.5. Food & Agriculture Testing
- 11.5.1. Pathogen Detection
- 11.5.2. Quality Monitoring
- 11.5.3. Soil Health Assessment

12. Metagenomic Sequencing Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. Metagenomic Sequencing Market, by Group

13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC

14. Metagenomic Sequencing Market, by Country

14.1. United States
14.2. China
14.3. Germany
14.4. Japan
14.5. India
14.6. United Kingdom
14.7. France
14.8. Canada
14.9. Italy
14.10. Australia
14.11. South Korea
14.12. Brazil
14.13. Mexico
14.14. Russia
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. 10x Genomics, Inc.
16.2. Agilent Technologies, Inc.
16.3. Azenta Life Sciences
16.4. BGI Group Co., Ltd.
16.5. Bio-Rad Laboratories, Inc.
16.6. BioMerieux SA
16.7. Complete Genomics, Inc.
16.8. Danaher Corporation
16.9. Eurofins Scientific SE
16.10. Illumina, Inc.
16.11. Integrated DNA Technologies, Inc.
16.12. Macrogen, Inc.
16.13. Merck KGaA
16.14. MGI Tech Co., Ltd.
16.15. Novogene Co., Ltd.
16.16. Oxford Nanopore Technologies Ltd.
16.17. Pacific Biosciences of California, Inc.
16.18. Promega Corporation
16.19. QIAGEN N.V.
16.20. Revvity, Inc.
16.21. Roche Holding AG
16.22. Thermo Fisher Scientific Inc.
16.23. Twist Bioscience Corporation
16.24. Zymo Research Corp.